Imugene Limited’s Leslie Chong speaks with Proactive’s Andrew Scott soon after the news that City of Hope® has dosed its first patient in the Phase I clinical trial of oncolytic virotherapy candidate, CHECKvacc. They’re investigating the safety and efficacy of Imugene’s CHECKvacc drug candidate — formally known as CF33-hNIS-antiPDL1 — against metastatic, triple-negative breast cancer.
source
